[Issues in vaccination against influenza A in Spain].
Identifieur interne : 000450 ( Main/Exploration ); précédent : 000449; suivant : 000451[Issues in vaccination against influenza A in Spain].
Auteurs : José M. Bayas Rodríguez [Espagne] ; Alberto L. García-Basteiro ; Guillermo Mena PinillaSource :
- Archivos de bronconeumologia [ 1579-2129 ] ; 2010.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A, Virus de la grippe A.
- prévention et contrôle : Grippe humaine.
- épidémiologie : Grippe humaine.
- Espagne, Humains, Pandémies.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- geographic : Spain.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A virus.
- prevention & control : Influenza, Human.
- Humans, Pandemics.
Abstract
Given the threat of an avian influenza A (H5N1) pandemic, vaccines that could be used in a new influenza pandemic began to be developed in 2004. The possible pandemic scenarios included highly serious situations with high incidence and mortality. Due to the need for the greatest possible number of vaccines to be available in a short period of time, studies with "model" vaccines were started, which allowed the immunogenicity and safety of the vaccines to be determined before identifying which virus would cause the pandemic. The use of adjuvants also formed part of these strategies. Subsequently, studies with the pandemic A (H1N1) strain were performed and additional studies continue to be performed. The vaccination strategies adopted have not been aimed at containing the infection but rather at ameliorating its effects. The choice of candidate groups for vaccination was not made hastily but after evaluating a large body of information on the epidemiology of the disease and the characteristics of the available vaccines. The population to be vaccinated is basically the same as that recommended to undergo seasonal influenza vaccination. In the ethical context of primum non nocere special emphasis has been placed on the vaccination of health personnel. All the available information supports the safety of the adjuvants and preservatives used in some of the authorized vaccines, as stated by the World Health Organization and many other prestigious organizations. So far 65 million doses have been administered throughout the world and the various adverse events detected by surveillance systems have been similar to those observed with other influenza vaccines and those that could be expected among millions of persons. Lessons must be drawn from the course of the present pandemic and the strategies used to deal with this situation as there will be other pandemics.
DOI: 10.1016/S0300-2896(10)70018-1
PubMed: 20353857
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Issues in vaccination against influenza A in Spain].</title><author><name sortKey="Bayas Rodriguez, Jose M" sort="Bayas Rodriguez, Jose M" uniqKey="Bayas Rodriguez J" first="José M" last="Bayas Rodríguez">José M. Bayas Rodríguez</name><affiliation wicri:level="3"><nlm:affiliation>Centro de Vacunación de Adultos, Servicio de Medicina Preventiva y Epidemiología, UASP, Hospital Clínic, Barcelona, España. jmbayas@clinic.ub.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Vacunación de Adultos, Servicio de Medicina Preventiva y Epidemiología, UASP, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Garcia Basteiro, Alberto L" sort="Garcia Basteiro, Alberto L" uniqKey="Garcia Basteiro A" first="Alberto L" last="García-Basteiro">Alberto L. García-Basteiro</name></author><author><name sortKey="Mena Pinilla, Guillermo" sort="Mena Pinilla, Guillermo" uniqKey="Mena Pinilla G" first="Guillermo" last="Mena Pinilla">Guillermo Mena Pinilla</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20353857</idno><idno type="pmid">20353857</idno><idno type="doi">10.1016/S0300-2896(10)70018-1</idno><idno type="wicri:Area/Main/Corpus">00473</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00473</idno><idno type="wicri:Area/Main/Curation">000473</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000473</idno><idno type="wicri:Area/Main/Exploration">000473</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Issues in vaccination against influenza A in Spain].</title><author><name sortKey="Bayas Rodriguez, Jose M" sort="Bayas Rodriguez, Jose M" uniqKey="Bayas Rodriguez J" first="José M" last="Bayas Rodríguez">José M. Bayas Rodríguez</name><affiliation wicri:level="3"><nlm:affiliation>Centro de Vacunación de Adultos, Servicio de Medicina Preventiva y Epidemiología, UASP, Hospital Clínic, Barcelona, España. jmbayas@clinic.ub.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Vacunación de Adultos, Servicio de Medicina Preventiva y Epidemiología, UASP, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Garcia Basteiro, Alberto L" sort="Garcia Basteiro, Alberto L" uniqKey="Garcia Basteiro A" first="Alberto L" last="García-Basteiro">Alberto L. García-Basteiro</name></author><author><name sortKey="Mena Pinilla, Guillermo" sort="Mena Pinilla, Guillermo" uniqKey="Mena Pinilla G" first="Guillermo" last="Mena Pinilla">Guillermo Mena Pinilla</name></author></analytic><series><title level="j">Archivos de bronconeumologia</title><idno type="eISSN">1579-2129</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Pandemics (MeSH)</term><term>Spain (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Espagne (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Pandémies (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Espagne</term><term>Humains</term><term>Pandémies</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Given the threat of an avian influenza A (H5N1) pandemic, vaccines that could be used in a new influenza pandemic began to be developed in 2004. The possible pandemic scenarios included highly serious situations with high incidence and mortality. Due to the need for the greatest possible number of vaccines to be available in a short period of time, studies with "model" vaccines were started, which allowed the immunogenicity and safety of the vaccines to be determined before identifying which virus would cause the pandemic. The use of adjuvants also formed part of these strategies. Subsequently, studies with the pandemic A (H1N1) strain were performed and additional studies continue to be performed. The vaccination strategies adopted have not been aimed at containing the infection but rather at ameliorating its effects. The choice of candidate groups for vaccination was not made hastily but after evaluating a large body of information on the epidemiology of the disease and the characteristics of the available vaccines. The population to be vaccinated is basically the same as that recommended to undergo seasonal influenza vaccination. In the ethical context of primum non nocere special emphasis has been placed on the vaccination of health personnel. All the available information supports the safety of the adjuvants and preservatives used in some of the authorized vaccines, as stated by the World Health Organization and many other prestigious organizations. So far 65 million doses have been administered throughout the world and the various adverse events detected by surveillance systems have been similar to those observed with other influenza vaccines and those that could be expected among millions of persons. Lessons must be drawn from the course of the present pandemic and the strategies used to deal with this situation as there will be other pandemics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20353857</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2011</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1579-2129</ISSN><JournalIssue CitedMedium="Internet"><Volume>46 Suppl 2</Volume><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archivos de bronconeumologia</Title><ISOAbbreviation>Arch. Bronconeumol.</ISOAbbreviation></Journal><ArticleTitle>[Issues in vaccination against influenza A in Spain].</ArticleTitle><Pagination><MedlinePgn>32-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0300-2896(10)70018-1</ELocationID><Abstract><AbstractText>Given the threat of an avian influenza A (H5N1) pandemic, vaccines that could be used in a new influenza pandemic began to be developed in 2004. The possible pandemic scenarios included highly serious situations with high incidence and mortality. Due to the need for the greatest possible number of vaccines to be available in a short period of time, studies with "model" vaccines were started, which allowed the immunogenicity and safety of the vaccines to be determined before identifying which virus would cause the pandemic. The use of adjuvants also formed part of these strategies. Subsequently, studies with the pandemic A (H1N1) strain were performed and additional studies continue to be performed. The vaccination strategies adopted have not been aimed at containing the infection but rather at ameliorating its effects. The choice of candidate groups for vaccination was not made hastily but after evaluating a large body of information on the epidemiology of the disease and the characteristics of the available vaccines. The population to be vaccinated is basically the same as that recommended to undergo seasonal influenza vaccination. In the ethical context of primum non nocere special emphasis has been placed on the vaccination of health personnel. All the available information supports the safety of the adjuvants and preservatives used in some of the authorized vaccines, as stated by the World Health Organization and many other prestigious organizations. So far 65 million doses have been administered throughout the world and the various adverse events detected by surveillance systems have been similar to those observed with other influenza vaccines and those that could be expected among millions of persons. Lessons must be drawn from the course of the present pandemic and the strategies used to deal with this situation as there will be other pandemics.</AbstractText><CopyrightInformation>Copyright © 2010 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayas Rodríguez</LastName><ForeName>José M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Centro de Vacunación de Adultos, Servicio de Medicina Preventiva y Epidemiología, UASP, Hospital Clínic, Barcelona, España. jmbayas@clinic.ub.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Basteiro</LastName><ForeName>Alberto L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Mena Pinilla</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Problemática de la vacunación contra la gripe A en España.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Bronconeumol</MedlineTA><NlmUniqueID>0354720</NlmUniqueID><ISSNLinking>0300-2896</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20353857</ArticleId><ArticleId IdType="pii">S0300-2896(10)70018-1</ArticleId><ArticleId IdType="doi">10.1016/S0300-2896(10)70018-1</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><noCountry><name sortKey="Garcia Basteiro, Alberto L" sort="Garcia Basteiro, Alberto L" uniqKey="Garcia Basteiro A" first="Alberto L" last="García-Basteiro">Alberto L. García-Basteiro</name><name sortKey="Mena Pinilla, Guillermo" sort="Mena Pinilla, Guillermo" uniqKey="Mena Pinilla G" first="Guillermo" last="Mena Pinilla">Guillermo Mena Pinilla</name></noCountry><country name="Espagne"><region name="Catalogne"><name sortKey="Bayas Rodriguez, Jose M" sort="Bayas Rodriguez, Jose M" uniqKey="Bayas Rodriguez J" first="José M" last="Bayas Rodríguez">José M. Bayas Rodríguez</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20353857
|texte= [Issues in vaccination against influenza A in Spain].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20353857" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |